EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations
EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations
These genotype combinations include the HTR3A, HTR3B, and SLC6A4 receptor sites, which are expected to play an important role in the company's precision medicine approach to treating addiction and may support the expansion of its pipeline.On Tuesday, Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced that patent number 12150931 was issued by the United States Patent and Trademark Office on November 26, expanding the company's intellectual property coverage.
周二，阿迪尔制药公司（纳斯达克股票代码：ADIL）宣布，美国专利商标局于11月26日发布了专利号12150931，扩大了该公司的知识产权覆盖范围。
The patent covers a broader range of genotype combinations identified by the company's proprietary genetic diagnostic for targeted treatment of alcohol use disorder (AUD) with AD04, the company's lead investigational new drug product.
该专利涵盖了更广泛的基因型组合，该组合由该公司专有的基因诊断系统确定，用于使用该公司主要的研究性新药产品AD04对酒精使用障碍（AUD）进行靶向治疗。
Also Read: EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder
另请阅读：独家：Adial Pharmicals推进了其酒精使用障碍主要计划的伴随诊断基因检测的监管战略
These genotype combinations include the HTR3A, HTR3B, and SLC6A4 receptor sites, which are expected to play an important role in the company's precision medicine approach to treating addiction and may support the expansion of its pipeline.
这些基因型组合包括 HTR3A、HTR30和 SLC6A4 受体位点，预计这些位点将在该公司治疗成瘾的精准医疗方法中发挥重要作用，并可能支持其产品线的扩展。
"This patent significantly enhances our intellectual property portfolio, providing us with greater flexibility and protection as we advance AD04 toward commercialization," said Cary Claiborne, CEO of Adial Pharmaceuticals.
艾迪尔制药首席执行官卡里·克莱伯恩表示：“这项专利极大地增强了我们的知识产权组合，在我们推进AD04商业化的过程中为我们提供了更大的灵活性和保护。”
The company says it has expanded patent coverage for AD04, focusing on its use in personalized medicine. This new patent strengthens the company's strategy to protect AD04 for treating AUD by covering all genotype combinations identified in our clinical program, ensuring intellectual property protection through 2031.
该公司表示，已经扩大了AD04的专利覆盖范围，重点是其在个性化医疗中的使用。这项新专利涵盖了我们临床项目中确定的所有基因型组合，从而加强了该公司保护AD04治疗澳元的战略，确保了到2031年为止的知识产权保护。
In November, Adial Pharmaceuticals completed a pharmacokinetics (PK) study of AD04 for Alcohol Use Disorder in heavy drinking patients (defined as less than ten drinks/drinking day).
11月，Adial Pharmaceuticals完成了一项针对大量饮酒患者（定义为每天饮酒少于十杯）酒精使用障碍的药代动力学（PK）研究。
The results showed that, due to the lower dose, AD04 0.33mg delivered lower ondansetron PK exposure than the marketed reference standard ondansetron 4mg tablet; ondansetron pharmacokinetic exposure increased in proportion to dose across a 3–fold AD04 dose range; and AD04 could be taken in fed or fasted states.
结果表明，由于剂量较低，AD04 0.33mg的恩丹西酮Pk暴露量低于市售参考标准昂丹司琼4mg片剂；在AD04的3倍剂量范围内，恩丹司琼药代动力学暴露量与剂量成比例增加；AD04可以在喂食或禁食状态下服用。
Price Action: At last check on Tuesday, ADIL stock was down 0.93% at $1.06 during the premarket session.
价格走势：在周二的最后一次检查中，ADIL股价在盘前交易时段下跌0.93％，至1.06美元。
- Generative AI-Backed Cybersecurity Stocks Cloudflare, Okta Have Near-Term Upside: Analyst
- 分析师：生成式人工智能支持的网络安全股票 Cloudflare、Okta 在短期内有上涨空间